Letrozolo Sun

Letrozole, the active ingredient in Letrozolo Sun, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozolo Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is an aromatase inhibitor used in the management of breast cancer and related endocrine pathways. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces risk of disease recurrence. - Advanced breast cancer (postmenopausal): Delays progression of tumor growth. - Metastatic breast cancer (postmenopausal): Improves overall survival outcomes.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint pain: Discomfort or aching in joints. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Feeling of sickness in the stomach.

Serious or Rare Side Effects: - Severe liver injury: Marked elevation of liver enzymes or hepatitis. - Bone fractures: Increased risk of osteoporosis‑related fractures. - Allergic reactions: Rash, swelling, or anaphylaxis.

Before initiating Letrozolo Sun, clinicians should consider several safety measures. - Bone health monitoring: Assess bone mineral density regularly. - Liver function testing: Check baseline and periodic liver enzymes. - Cardiovascular risk assessment: Evaluate history of thromboembolic events. - Drug hypersensitivity review: Avoid use in patients with known letrozole allergy. - Concomitant medication review: Adjust doses of drugs metabolized by CYP3A4. - Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Letrozolo Sun can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase letrozole plasma levels. - Estrogen replacement therapy: Counteracts aromatase inhibition effect. - Tamoxifen: Reduces therapeutic efficacy when combined.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): May modestly raise letrozole concentrations. - CYP2C8 inhibitors (e.g., gemfibrozil): Can affect metabolism. - Warfarin: May enhance anticoagulant effect, requiring INR monitoring.